February 7, 2019 – researchers from Johns Hopkins said the active ingredient in hallucinogenic mushrooms – psilocybin – has low abuse potential, and could reduce psychological distress and opioid abuse potential they would recommend reclassifying psilocybin from a schedule I drug – one that has no known medical potential – to a schedule IV drug – one that has low potential for abuse and dependence.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…